Abstract: Personalized treatment is highly desirable in multiple sclerosis (MS). We believe that multidisciplinary measurements including clinical, functional and patient-reported outcome measures in combination with extensive patient profiling can enhance personalized treatment and rehabilitation strategies. We elaborate on four reasons behind this statement: (1) MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description, (2) functioning, progression, treatment, and rehabilitation effects are interdependent and should be investigated together, (3) personalized healthcare is based on the dynamics of system biology and on technology that confirms a patient's fundamental biology and (4) inclusion of patient-reported outcome measures can facilitate patient-relevant healthcare. We discuss currently available multidisciplinary MS data initiatives and introduce joint actions to further increase the overall success. With this topical review, we hope to drive the MS community to invest in expanding towards more multidisciplinary and longitudinal data collection.
Introduction
Management of multiple sclerosis (MS) comprises a wide range of drugs with different modes of action, a broad spectrum of proposed rehabilitation strategies and varying levels of efficacy that need meticulous monitoring. Diverse high-quality data are needed for many different purposes. Regulators need data for lifecycle assessment, effectiveness and safety of medicines in clinical practice. Health technology assessment (HTA) bodies want to incorporate data from clinical practice into the drug development process. Researchers want to get a better understanding of the disease, and neurologists wish to build decision-support systems to support MS diagnosis, prognosis and treatment. We believe that multidisciplinary measurements (as summarized in Figure 1 ) including clinical, functional and patient-reported outcome measures (PROMs) in combination with extensive patient profiling (including immunology, genetics, etc.) can enhance personalized treatment (=medical and rehabilitation). In this paper, we elaborate on different reasons for this statement. We discuss currently available multidisciplinary MS data initiatives and propose future steps to jointly move forward.
Four reasons why consistent longitudinal multidisciplinary screening is required
One could question whether multidisciplinary evaluation is truly superior, as it often requires a multidisciplinary team that is larger than the neurologist and nurse. Here, we elaborate on four reasons why we believe the additional efforts are worth it.
Reason 1. MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description.
'Progression' or 'deterioration' can occur in the motor, visual and sensory systems but can also refer to cognitive changes, fatigue, bowel and bladder function, sexual dysfunction, quality of life as well as work Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! productivity and activity. Most measures focus primarily on physical disability. Indeed, a commonly used outcome measure is the Expanded Disability Severity Score (EDSS). However, the limitations of EDSS are well known. 1 Physical disability in mobility and upper limb function is of great importance in MS. However, to encompass the multidimensional aspects of MS, there is an urgent need to also define standard and comprehensive packages of measures that capture cognitive, psychological, emotional life function impacting quality of life. 2 A single measure of sustained disease progression may remain elusive. Rather, an integration of current and new outcome measures may be most appropriate, and utilization of different measures depending on the MS population and stage of the disease may be preferred. Composite measures including multiple accepted measures could be superior to any of the single measurements in analysing progression. Several of these measures have been introduced. A well-know example is the multiple sclerosis functional composite (MSFC). 3 Another example is the 'EDSS Plus', adding the timed-25-foot walk and the Nine-Hole Peg Test to EDSS, as an improved endpoint to identify disability progression in secondary progressive MS. 4 It is noted, however, that components like fatigue and quality of life are still not integrated in these composite scores.
Reason 2. Functioning, progression, treatment and rehabilitation effects are interdependent and should be investigated together There is increasing evidence that an active lifestyle can affect co-morbidity, cognitive and mobile function and quality of life. Next to this, cognitive and physical interventions have been shown to impact structural and functional neuroplasticity. 5 It is suggested that there may be a neuroprotective or even neuro-restorative effect of physical exercise, 6 while it is known that exercise can reduce elements of cognitive impairment, fatigue and depression. 7 Fatigue self-management programmes were shown to be effective to reduce fatigue and likely the participation to society of person with multiple sclerosis (PwMS). 8 Other examples of effective rehabilitation treatment can be provided in the domain of cognitive function. 9 In fact, it is believed that high activity in the motor and cognitive domain is extremely important in order to enhance motor and cognitive neural reserve and delay progression, even in the early MS phase. 10 Overall, there is a need of a large cohort sample with comprehensive data to demonstrate the interactions more clearly.
The international classification of functioning (ICF) distinguishes the levels of body function and structures, activities and participation, influenced by environmental and personal factors. All domains are considered to be potentially interlinked and might even affect the disease pathophysiology itself. 11 A core set of the ICF has been developed for MS and can be applied to characterize the functional domains where limitations can occur in MS. 12 For example, ambulatory dysfunction, cognitive dysfunction and fatigue are very common throughout the disease course and have great impact on physical activity, mood, quality of life and social participation. 13 Similarly, lifestyle factors affect physical and cognitive functions with active lifestyles being hypothesized to be protective. Currently, one is observing a trend to integrate data on functioning in the electronic health records. 11 Reason 3. Personalized healthcare is based on the dynamics of system biology and on technology that confirms a PwMS' fundamental biology Considerable research effort is invested to understand the impact of the individual PwMS' molecular profile on disease activity and progression. In the absence of single, highly predictive markers, personalization will depend on clusters of markers in multiple models. Sensitive markers of disease markers are emerging, for example, monitoring cerebrospinal fluid (CSF) or serum neurofilament light (Nf-L) chain concentration. 14 Furthermore, the prognostic value of CSF oligoclonal band (OCB) has been investigated and validated by several researchers. More research is necessary for other less well validated but possibly important candidate prognostic and diagnostic markers in CSF and serum. Variations in genes may play a role in MS susceptibility and disease progression; genome-wide association studies (GWAS) uncovered more than 300 implicated genetic loci, each which moderates to low odds ratios. 15 Finally, including data on immunological subset phenotyping in decisionsupport systems could be a valuable approach. 14, 16 Insights in the relative importance of these different factors in combination with increased knowledge on how these factors interact will be extremely valuable for tailoring the therapy of individual PwMS. It will also lead to better understanding of the involved processes and pathways in MS.
Reason 4. Inclusion of PROMs can facilitate patientrelevant healthcare
With a shift towards patient-relevant healthcare, patient and person reports of health-related factors are seen as important determinants for evaluating and improving healthcare. Including 'hidden' symptoms like fatigue, cognition, depression in data-driven (regulatory) decision-making processes is an urgent unmet need for patients. 17 PROMs are defined, as 'any report of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else'. 18 A comprehensive, systematic categorization of patient and person reports is currently lacking in literature, even though several methods are used to measure patient reports. PROMs could offer significant advantages over assessment by a physician: they better capture the impact of disease on the person; they are often easier and cheaper to record; and they can often be completed from the home environment, potentially enabling long-term, geographically diverse, and large-scale observational and interventional studies with shorter intervals between time-points as compared to only recording physicianbased outcome measures. 19 For example, the multiple sclerosis walking scale (MSWS), encompassing many dimensions of mobility and mental effort during walking, is increasingly accepted in clinical trials as outcome measure. 20 
Current observational multidisciplinary MS data initiatives
A growing number of MS databases and registries have started to produce long-term outcome data from large cohorts of PwMS treated with disease-modifying therapies in real-world settings. Multidimensional patient documentation systems are developed to support these data collection. For example, the multiple sclerosis documentation system (MSDS) allows data collection and communication between PwMS, MS nurses and neurologists. 21 Other examples of innovative comprehensive MS-specific electronic data-capture systems are the Knowledge Programme 22 and MS Bioscreen. 23 Many other efforts contributed to the development of better data infrastructures. In 2017, Bebo et al. 24 performed a landscape analysis of MS patient registries and cohorts and revealed a significant number of independent parallel studies. Several cohorts collect both physician-as well as patient-reported outcomes (e.g. 24 Another promising and recently launched example of multidimensional screening is the multicentre collaboration named 'MS paths', which is extending the Cleveland Clinical Knowledge programme as well as adding biobanking (www.mspaths.com).
There is increasing international interest to collaborate and share data among different stakeholders. 25, 26 There are several reasons to share (and not share) data and to use (or not use) shared data which are illustrated in Figure 2 . Policies of data sharing should rest upon knowledge of how data are shared and how end-users use data that have been shared to them. To ensure that both sharing data and using shared data are encouraged, a community of trust and transparency is required. Global collaborations to address, at low cost, additional important questions about patient natural history, medicine efficacy and adverse events are being pioneered by the MSBase consortium and similar organizations. MSBase is a web-platform designed to collect prospective MS data. It enables participating neurologists to contribute data on diagnosis, treatment and progress, to review anonymous aggregated data and to benchmark their patient population against other patient subsets or the entire data set. 27 For example, Kalincik et al. 28 constructed predictive models based on demographic, clinical and functioning information to support predictions of individual response of PwMS to disease-modifying therapies at baseline.
Proposition of joint action steps to shape the future We propose in the following paragraphs several joint actions to further increase the success rate of consistent longitudinal multidisciplinary screening:
Joint action 1. Inclusion of multidisciplinary staff in the data collection process.
Sorensen et al. describe the urgent need for the international implementation of multidisciplinary care units for MS. 29 We propose to include data routinely collected and shared by multidisciplinary teams including the neurologists, rehabilitation physician, ophthalmologists, radiologists, clinical and research nurses, physiotherapists, psychologists, occupational therapist, speech therapists and PwMS or PwMS' relatives. Indeed, a pilot study showed that an integrated, multidisciplinary programme to address unsafe use of opioids prescribed for pain was effective in a group of Figure 2 . Data sharing requires a community of trust and transparency: there are several reasons to share (and not share) data and to use (or not use) the shared data. Policies of data sharing should rest upon knowledge of how data are shared and how end-users use data that have been shared to them. To ensure that both sharing data and using shared data are encouraged, a community of trust and transparency is required.
high-complexity patients. 30 Next to this, a pragmatic randomized controlled trial referred to as 'the Danish MS Hospitals Rehabilitation Study' 31 indicated that inpatient multidisciplinary rehabilitation is effective in improving health-related quality of life in MS patients.
In Table 1 , we present variables that, among others, could be included in a multidisciplinary data infrastructure categorized according to a potential primary data collector.
Joint action 2. Agreement on minimal data sets meaningful to PwMS
It is encouraged that large projects include a shared data set or apply the commonly accepted and scientific robust measures. For example, the systematic exploitation of minimal data set as a data source in the detection of malignant tumours has shown to be a valuable tool in the monitoring of cancer. 32 Community efforts are undertaken to harmonize and define a minimal data set. Defining a 'minimal data set' is challenging and requires discussions and consensus between all stakeholders involved. The National Institute of Neurological Disorders and Stroke (NINDS) developed a first set of Common Data Elements for MS in 2011 (www.commondataelements.ninds.nih.gov). In 2015, the European Medicines Agency (EMA) 33 set up an initiative to make better use of existing registries and facilitate the establishment of high-quality new registries, providing an adequate source for postauthorization data for regulatory decision-making. MS and cystic fibrosis were the selected conditions chosen for the pilot phase of this initiative. During a workshop on MS registries in July 2017, a first draft of a minimal data set to support long-term longitudinal post-authorization safety studies was proposed. 34 For now, limited emphasis is put on including patient-reported and functional outcome measures. Although a plentitude of outcome measures has been developed and applied, there is increasing agreement on the dimensions of functioning that should be measured and on appropriate and commonly accepted outcome measures.
Researchers are also increasingly labelling and selecting standard outcome measures according to the ICF framework. 35 It may serve as a conceptual framework for on-going initiatives of the Multiple Sclerosis International Federation (MSIF) in collaboration with international partner associations to focus on patientrelevant outcomes. The multiple sclerosis outcome assessment consortium (MSOAC) has reconfirmed the T25FW and 9HPT as reference standards for measuring walking speed and manual dexterity as part of the MSFC. 36, 37 Besides, MSOAC advocates the use of the symbol digit modality test (SDMT) instead of the paced serial addition test (PASAT) for the domain of cognitive function, added with the low-contrast letter acuity for visual function as part of a standard test battery. 38 Second, an overview of commonly accepted multidisciplinary tests was published based on a multistakeholder pan-European meeting. 39 Ideally, we could also come to a consensus concerning a minimal data set for MRI outcome measures, serum and CSF biomarkers and/or genetic risk factors. However, before we get there, much more research is necessary on the relative importance of these factors. Several consortia, initiatives and projects focus on overcoming these challenges. Powerful examples here are Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) and The International Multiple Sclerosis Genetics Consortium (IMSGC). More research is necessary to investigate the relative importance of these genetic risk factors and also to identify gene variants that influence progression in MS. We anticipate steps forward concerning these major unmet needs because of several synergistic and collaborative initiatives focussing on this topic. For example, MultipleMS (www.multipleMS.eu) aims to identify a combination of clinical, biological and lifestyle biomarkers that can predict the clinical course, stratify patients based on their risk and the therapeutic response to the existing disease-modifying treatments (DMTs), thus spearheading the development of personalized medicine (Ingrid Kockum, personal communication).
Joint action 3. Implementation of standards and common data models (CDMs) in data collection procedures
A first step to increase interoperability between databases is to define standard protocols to measures outcomes. Especially for the functional and PRO, no standards are available yet and need to be defined. For adoption in research and clinical practice, it is required that outcome measures are standardized, have demonstrated psychometric properties (test-retest reliability, discriminant and content validity and sensitivity to change) and clinical utility. The implementation of internationally approved standards could greatly increase the possibilities to connect and pool data sets. More and more MS-specific IT platforms are incorporating standards to label variables. For example, data standards for MS were established by the Clinical Data Interchange Standards Consortium (CDISC) (http://www.cdisc.org/standards/therapeutic-areas/multiple-sclerosis). Next to this, the EMA workshop highlighted the need to include the Medical 42 The Clinical Building Blocks are an initiative of the eight Dutch University Medical Centres (UMCs) to work together on the standardization of healthcare data and are used by healthdata.be to integrate data from various sources to a decentralized healthcare system. 43 Especially for multidisciplinary data sets, where even local collaboration between physicians, researchers and PwMS is required, the need to move towards 'independent data infrastructures' is timely and urgent. Figure 3 visualizes the difference between IT-dependent and IT-independent data infrastructures.
Integrating data from various sources is a particular challenge in decentralized healthcare systems and can require substantial investment in technical solutions and political will to overcome long-standing fragmentation. In order for IT-independent data infrastructures to succeed, the implementation of standards and CDMs is required.
Conclusion
If detailed clinical, functional and patient-reported data are accompanied by both MRI of the central nervous system and biological samples, significant insight into MS pathophysiology could be achieved. Still, data collection is extremely expensive and time-consuming. Policymakers and regulatory authorities clearly show an increased interest to include real-world data evidence in their decision-making processes. However, sustainable funding strategies to support long-term multidimensional profiling of PwMS are required. Public-private partnerships might be one of the solutions to overcome these hurdles. Indeed, more generic IMI projects like the EHDEN project are arising. Next to this, prospective observational long-term safety surveillance studies to investigate post-authorization safety using real-world evidence data are currently being piloted. Collaborations between marketing authorization holders/applicants and MS registries/cohorts might raise opportunities to sustainably support collection of quality data. Important projects can happen by seeking out admirable partners and diverse collaborators who are willing to share ideas, share work and share data. With improvements in technology, tools and communication, it is becoming easier to collect, save, manage, distribute and reuse data. However, the slow adaptation of tools and services such as data repositories are indications that technology alone cannot change scientific practices; other social and cultural factors must also encourage data sharing. It is important that technical solutions as well as governance solutions are developed in order to enable an ecosystem in which all stakeholders are comfortable.
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